Wellgistics Health Inc. Reports Major Expansion in Q2 2025 with 116 New Manufacturer Partnerships and Over 12,400 New Products

Reuters
25 Jun
<a href="https://laohu8.com/S/WGRX">Wellgistics Health Inc.</a> Reports Major Expansion in Q2 2025 with 116 New Manufacturer Partnerships and Over 12,400 New Products

Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare technology company focused on revolutionizing prescription access and distribution, announced significant Q2 2025 operational results. The company has expanded its platform with 116 new pharmaceutical manufacturer partnerships, over 12,400 new products (NDCs), and more than 275 pharmacies added to its national network. This growth is part of Wellgistics' strategy to create a modern drug ecosystem that connects manufacturers directly to pharmacies, providers, employers, and patients. The platform aims to streamline fulfillment, reduce costs, and bypass legacy bottlenecks through a fully integrated, AI-powered infrastructure. As Wellgistics advances toward direct-to-patient care programs, it plans to leverage its expanding distribution, fulfillment, and pharmacy network to support new models of care, aligning pharmaceutical manufacturers with a streamlined path to market while offering patients faster, more transparent prescription access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042848) on June 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10